38. Aceves, C., et al. (2005). Is iodine a gatekeeper of the integrity of the mammary gland? J Mammary Gland Biol Neoplasia, 10, 189–196.
39. Eskin, B. A., et al. (1967). Mammary gland dysplasia in iodine deficiency. JAMA, 200, 115–119.
40. Lockwood, K., et al. (1994). Partial and complete regression of breast can-cer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Comm, 199 (3), 1504–1508.
41. Ye, S. F., et al. (2003). Suppressive effects of Active Hexose Correlated Compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci, 74, 593–602.
42. Ikeda, T., et al. (2003). Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal Candida albicans infection in experimental granulocytopenic mice. Nippon Ishinkin Gakkai Zasshi, 44, 127–131; Aviles, H., et al. (2003). Active hexose correlated compound enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol, 95, 491–496; Wang, S., et al. (2009). Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr 139, 598–602.
43. Matsui, Y., et al. (2002). Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol, 37, 78–86.
44. Larsson, S. C., et al. (2010). Multivitamin use and breast cancer incidence in a prospective cohort of Swedish women. Am J Clin Nutr, 91, 1268–1272.
45. Meulepas, J. M., et al. (2010). Multivitamin supplement use and risk of invasive breast cancer. Public Health Nutr, 13 (10), 1540–1545; Ishitani, K., et al. (2008). A prospective study of multivitamin supplement use and risk of breast cancer. Am J Epidemiol, 167, 1197–1206; Zhang, S., et al. (1999). A prospective study of folate intake and the risk of breast cancer. JAMA, 281, 1632–1637.
46. Pierce, B. L., et al. (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol, 27, 3437–3444.
47. Li, C. I., et al. (2010). Alcohol consumption risk of postmenopausal breast cancer by subtype: The women’s health initiative observational study. J Natl Cancer Inst, 102, 1422–1431.
48. Willett, W. C., et al. (1987). Moderate alcohol consumption and the risk of breast cancer. N Engl J Med, 316, 1174–1180.
49. Li, C. I., et al. (2009). Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor–positive invasive breast cancer. J Clin Oncol, 27, 5312–5318.
50. Ginsburg, E. (1996). Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA, 276 (21), 1747–1751.
51. Zhang, S., et al. (1989). A prospective study of folate intake and the risk of breast cancer. JAMA, 281 (17), 1632–1637.
52. Ambrosone, C., et al. (1996). Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA, 276 (18), 1494–1501.
53. Bernstein, L., et al. (2005). Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst., 97 (22), 1671–1679.
54. Thune, I., et al. (1997). Physical activity and the risk of breast cancer. N Engl J Med, 336, 1269–1275.
55. Peters, T. M., et al. (2009). Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: The prospective NIH-AARP diet and health study. BMC Cancer, 9, 349.
56. Verkasalo, P. K., et al. (2005). Sleep duration and breast cancer: A prospective cohort study. Cancer Res, 65 (20), 9595–9600.
57. Blask, D. E., et al. (2005). Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res, 65 (23), 11174–11184.
58. Schernhammer, E. S., & Hankinson, S. E. (2005). Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst, 97 (14), 1084–1087.
59. Schernhammer, E. S., et al. (2001). Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst, 93 (20), 1563–1568.
60. Glass, A. G., et al. (2007). Breast cancer incidence, 1980–2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst, 99, 1152–1161; Ravdin, P. M., et al. (2007). The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 356, 1670–1674; Clarke, C. A., et al. (2006). Recent declines in hormone therapy utilization and breast cancer incidence: Clinical and population-based evidence. J Clin Oncol, 24, e49–e50.
61. Welch, H. G., & Black, W. C. (1997). Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: How much more breast cancer can we find? Ann Intern Med, 127 (11), 1023–1028; Nielsen, M., et al. (1987). Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br J Cancer, 56 (6), 814–819.
62. Welch, H. G., & Black, W. C. (1997). Op. cit., 1023.
63. Zahl, P., Maehlen, J., & Welch, H. G. (2008). The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med, 168, 21, 2311–2316.
64. Parker-Pope, T. (Oct. 22, 2009). Benefits and risks of cancer screening are not always clear, experts say. New York Times, A26 (also available online at http://www.nytimes.com/2009/10/22/health/22screen.html#); Esserman, L., et al. (2009). Rethinking screening for breast cancer and prostate cancer. JAMA, 302, 1685–1692; Kolata, G. (Oct. 21, 2009). Cancer society, in shift, has concerns on screenings. New York Times, A1 (also available online at www.nytimes.com/2009/10/21/health/21cancer.html#).
65. Parker-Pope, T. (Oct. 22, 2009). Op. cit.
66. Moody-Ayers, S., et al. (2000). “Benign” tumors and “early detection” in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med, 160 (8), 1109–1115.
67. National Institutes of Health Consensus Development Panel. (1997). National Institutes of Health Consensus Development Conference Statement: Breast cancer screening for women ages 40–49. J Natl Cancer Inst, 89 (14), 1015–1026.
68. Prager, K. (1996). Outrage over mammogram screening unwarranted. Medical Tribune. Quoted by Gina Kolata in the New York Times (Jan. 28, 1997).
69. Baines, C. (2005). Rethinking breast screening—again. BMJ, 331, 1031.
70. Van Netten, J. P., et al. (1994). Physical trauma and breast cancer. Lancet, 343 (8903), 978–979.
71. Christiansen, C. L., et al. (2000). Predicting the cumulative risk of falsepositive mammograms. J Natl Cancer Inst, 92 (20), 1657–1666.
72. Elmore, J. G., et al. (1998). Ten-year risk of false positive screening mammograms and clinical breast exams. N Engl J Med, 338 (16), 1089–1096.
73. Gotzsche, P. C., & Olsen, O. (2001). Is screening for breast cancer with mammography justifiable? Lancet, 355, 129–134; Gotzsche, P. C., &Olsen, O. (2001). Cochrane review on screening for breast cancer with mammography. Lancet, 358, 1340–1342.
74. Miller, A. B., et al. (2000). Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst, 92, 18, 1490–1499.
75. Kerlikowske, K., et al. (1999). Continuing screening mammography in women aged 70 to 79 years: Impact on life expectancy and costeffectiveness. JAMA, 282, 22, 2156–2163.
76. Bleicher, R. J., et al. (2009). Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg, 209, 180–187.
77. Parisky, Y. R., et al. (2003). Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions. Am J Roentgenol, 180, 263–269.
78. Bronzino, J. D. (ed.) (2006). Medical Devices and Systems (The Biomedical Engineering Handbook). Boca Raton: CRC Press/Taylor & Francis Group.
79. Gautherie, M., & Gros, C. M. (1980). Breast thermography and cancer risk prediction
. Cancer, 45, 51–56.
80. Arora, N., et al. (2008). Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer. Am J Surg, 196, 523–526.
81. Moore, F. (1978). Breast self-examination. N Engl J Med, 299 (6), 304–305.
82. Thomas, D. B., et al. (2002). Randomized trial of breast self-examination in Shanghai: Final results. J Natl Cancer Inst, 94, 1445–1457.
83. Semiglazov, V. F., et al. (1999). Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO). Voprosy Onkologii, 45 (3), 265–271.
84. U.S. Preventive Services Task Force (Nov. 17, 2009). Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 151, 716–726; also available online at www.annals.org/content/151/10/716.full.
85. Wyrick, D. (2005). Personal communication. Dana Wyrick is a registered massage therapist who developed this self-massage routine for breast health after studying with lymphedema therapy specialists in Europe and Australia, where the technique is far more common.
86. U.S. Preventive Services Task Force (Nov. 17, 2009). Op. cit.
87. Mandelblatt, J. S., et al. (2009). Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms. Ann Intern Med, 151 (10), 738–747; also available online at www.annals.org/content/151/10/738.full.
88. Kerlikowske, K., et al. (1993). Positive predictive value of screening mammography by age and family history of breast cancer. JAMA, 270 (2), 444.
89. National Council on Aging (1997). Myths and Perceptions About Aging and Women’s Health. Washington, D.C. (1997). Assessing the odds. Lancet, 350 (9091), 1563.
90. Love, S. (2005). Dr. Susan Love’s Breast Book (145). Cambridge, MA: Da Capo Lifelong Books.
91. Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Kleg, L., & Edwards, B. K. (eds.) (2000). SEER Cancer Statistics Review, 1973–1993. Bethesda, MD: National Cancer Institute; Black, W. C., et al. (1995). Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years old. J Nat Cancer Inst, 87, 720–731.
92. Phillips, K. A. (1999). Putting the risk of breast cancer in perspective. N Engl J Med, 340 (2), 141–144.
93. Hirshaut, Y., & Pressman, P. (2000). Breast Cancer: The Complete Guide (256). New York: Bantam.
94. American College of Obstetrics & Gynecology, Committee on Genetics (Oct. 1996). Breast-Ovarian Cancer Screening (Committee Opinion no. 176). Washington, D.C.
95. Collins, F. S. (1986). BRCA1—lots of mutations, lots of dilemmas. N Engl J Med, 334 (3), 186–188.
96. Weisberg, T. (Oct. 1996). Genetic testing for breast cancer. Maine Cancer Perspectives, 2 (4), 3.
97. Kesaniemi, Y. A. (unpublished data). Cited in A. Viitanen (1996), A new estrogen gel: Clinical benefits. In B. G. Wren (ed.), Progress in the Management of the Menopause: The Proceedings of the 8th International Congress on the Menopause (168). Sydney, Australia: Parthenon.
98. LaVecchia, C., Negri, E., Franceschi, S., et al. (1995). Hormone replacement therapy and breast cancer risk: A cooperative Italian study. Br J Cancer, 72, 244–248.
99. Beral, V., et al. (2010). Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Nat Cancer Inst. 103, 296–305.
100. Campagnoli, C., et al. (1999). HRT and breast cancer risk: A clue for interpreting the available data. Maturitas, 33, 185–190; Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancer. Lancet, 350, 1047–1059.
101. Chlebowski, R. T., et al. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304, 1684–1692.
102. Bhavani, B. R., et al. (1994). Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta-dihydroequilin in normal postmenopausal women. J Clin Endocrinol Metab, 78, 197–204.
103. Hargrove, J., & Eisenberg, E. (1995). Menopause. Med Clin North Am, 79 (6), 1337–1363.
104. Campagnoli, C. (1999). Op. cit.; Collaborative Group on Hormonal Factors in Breast Cancer (1997). Op. cit.
105. Beral V., Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362 (9382), 419–427.
106. Coombs, N. J., et al. (2005). Hormone replacement therapy and breast cancer: Estimate of risk. BMJ, 331 (7512), 347–349.
107. Coombs, N. J., et al. (2005). Hormone replacement therapy and breast cancer risk in California. Breast J, 11 (6), 410–415.
108. Campagnoli, C. (1999). Op. cit. Given the results of the WHI study on Prempro and the financial losses suffered by Wyeth Ayerst as a result, it’s doubtful that we’ll ever have the data needed to prove this!
109. Fournier, A., et al. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the e3n cohort study. Breast Cancer Res Treat, 107, 103–111.
110. Fournier, A., et al. (2009). Estrogen-progestogen menopausal hormone therapy and breast cancer; does delay from menopause onset to treatment initiation influence risks? Journal of Clinical Oncology, 27, 5138–5143.
111. Huang, Z., Willett, W. C., Colditz, G. A., Hunter, D. J., Manson, J. E., Rosner, B., Speizer, F. E., & Hankinson, S. E. (1999). Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am J Epidemiol, 150 (12) 1316–1324. “Furthermore,” they write, “it has been proposed that abdominal adiposity is associated with an excess of androgen and increased conversion of androgen to estrogen in adipose tissue.” They also point out that hormone use by postmenopausal women likely raises hormone levels in all those women. “[A]s a result, all postmenopausal hormone users were at increased risk of breast cancer regardless of central obesity,” they reason.
112. Melamed, M., et al. (1997). Molecular and kinetic basis for the mixed agonist/ antagonist activity of estriol. Mol Endocrinol, 11, 12, 1868–1878.
113. Rajkumar, L., et al. (2004). Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res, 6, 1, R31–7.
114. Chlebowski, R., et al. (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med, 360 (6), 573–587.
115. Henrich, J. B. (1992). The postmenopausal estrogen/breast cancer controversy. JAMA, 268, 1900–1902; Wotiz, H. H., Beebe, D. R., & Muller, E. (1984). Effect of estrogen on DMBA-induced breast tumors. J Steroid Biochem, 20, 1067–1075.
116. Drife, J. O. (1986). Breast development in puberty. Ann N Y Acad Sci, 464, 58–65; Dulbecco, R., et al. (1982). Cell types and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A, 79, 7346–7350; Long-acre, T., & Bartow, S. (1986). A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surgical Path, 10 (6), 382–393; Weinberg, R. A. (Sept. 1996). How cancer arises. Scientific American, 62–70.
117. Lemon, H. (1973). Oestriol and prevention of breast cancer. Lancet, 1 (802), 546; Lemon, H. (1975). Estriol prevention of mammary carcinoma induced by 7,12-dimethyl-benzanthracene and procarbazine. Cancer Res, 35, 1341–1353; Lemon, H. (1980). Pathophysiologic considerations in the treatment of menopausal patients with oestrogens: The role of oestriol in the prevention of mammary cancer. Acta Endocrinol, 1, 17–27; Lemon, H., Wotiz, H., Parsons, L., et al. (1966). Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA, 196, 1128–1136.
118. Bu, S. Z., et al. (1997). Progesterone induces apoptosis and upregulation of p53 expression in human ovarian carcinoma cell lines. Cancer, 79 (10), 1944–1950.
119. Zava, D. T., & Duwe, G. (1997). Estrogen and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vivo. Nutr Cancer, 27 (1), 31–40.
120. Cowan, A. D., et al. (1961). Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol, 114 (2), 209.
121. Chang, K. J., et al. (1995). Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril, 63, 785–791.
122. Badwe, R. A., et al. (1991). Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet, 337, 1261–1264.
123. Hrushesky, W. (1996). Breast cancer, timing of surgery, and the menstrual cycle: Call for prospective trial. J Womens Health, 5 (6), 555–566.
124. Wren, B., & Eden, J. A. (1996). Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause, 3 (1), 4–12.
125. Ibid.
The Wisdom of Menopause Page 88
